Leerink Swann Analysts Raise Earnings Estimates for Retrophin Inc (RTRX)

Retrophin Inc (NASDAQ:RTRX) – Leerink Swann upped their FY2017 earnings estimates for Retrophin in a research note issued to investors on Wednesday. Leerink Swann analyst J. Schwartz now anticipates that the biopharmaceutical company will earn ($1.18) per share for the year, up from their previous forecast of ($1.20). Leerink Swann also issued estimates for Retrophin’s Q4 2017 earnings at ($0.09) EPS, FY2018 earnings at ($0.79) EPS, FY2019 earnings at ($0.91) EPS and FY2020 earnings at ($0.66) EPS.

Retrophin (NASDAQ:RTRX) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.21). The firm had revenue of $40.34 million during the quarter, compared to analysts’ expectations of $40.51 million. Retrophin had a negative return on equity of 10.13% and a negative net margin of 33.79%. The company’s quarterly revenue was up 18.8% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.09) earnings per share.

A number of other brokerages also recently weighed in on RTRX. BMO Capital Markets reaffirmed a “buy” rating and issued a $44.00 target price on shares of Retrophin in a research note on Friday, October 6th. Zacks Investment Research raised shares of Retrophin from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 4th. BidaskClub raised shares of Retrophin from a “hold” rating to a “buy” rating in a research note on Wednesday, January 10th. Finally, ValuEngine downgraded shares of Retrophin from a “hold” rating to a “sell” rating in a research note on Monday, November 20th. Two investment analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. Retrophin currently has an average rating of “Hold” and a consensus target price of $44.00.

Shares of Retrophin (RTRX) opened at $24.70 on Monday. The firm has a market cap of $970.88, a P/E ratio of -16.36 and a beta of 0.96. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.88 and a quick ratio of 3.83. Retrophin has a one year low of $15.55 and a one year high of $26.44.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Nationwide Fund Advisors raised its stake in Retrophin by 14.6% in the second quarter. Nationwide Fund Advisors now owns 59,424 shares of the biopharmaceutical company’s stock valued at $1,152,000 after purchasing an additional 7,583 shares in the last quarter. Prudential Financial Inc. purchased a new position in shares of Retrophin during the second quarter worth approximately $775,000. Schwab Charles Investment Management Inc. raised its stake in shares of Retrophin by 35.7% during the second quarter. Schwab Charles Investment Management Inc. now owns 277,688 shares of the biopharmaceutical company’s stock worth $5,385,000 after acquiring an additional 73,067 shares in the last quarter. Strs Ohio purchased a new position in shares of Retrophin during the third quarter worth approximately $908,000. Finally, JPMorgan Chase & Co. raised its stake in shares of Retrophin by 4.3% during the second quarter. JPMorgan Chase & Co. now owns 137,526 shares of the biopharmaceutical company’s stock worth $2,667,000 after acquiring an additional 5,674 shares in the last quarter.

ILLEGAL ACTIVITY WARNING: This article was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://stocknewstimes.com/2018/01/15/leerink-swann-analysts-raise-earnings-estimates-for-retrophin-inc-rtrx.html.

About Retrophin

Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply